Literature DB >> 26449194

Comment on 'Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results'.

V P Dave1.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26449194      PMCID： PMC5129810          DOI： 10.1038/eye.2015.190

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  3 in total

1.  Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema.

Authors:  Masoud Soheilian; Kiumars Heidari Garfami; Alireza Ramezani; Mehdi Yaseri; Gholam A Peyman
Journal:  Retina       Date:  2012-02       Impact factor: 4.256

2.  Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results.

Authors:  N Homer; D S Grewal; R G Mirza; A T Lyon; M K Gill
Journal:  Eye (Lond)       Date:  2015-05-29       Impact factor: 3.775

3.  Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.

Authors:  Allen C Ho; Brandon G Busbee; Carl D Regillo; Mark R Wieland; Sherri A Van Everen; Zhengrong Li; Roman G Rubio; Phillip Lai
Journal:  Ophthalmology       Date:  2014-07-09       Impact factor: 12.079
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.